The mechanisms involved in BCC resistance are not only related to mutations in the canonical Hh pathway, therefore Whitson et al. have shown in a mouse model that the activation of non-canonical Hh pathway by MKL1/SRF is related to the resistance to SMO inhibitors in some BCCs. The gene discussed is SRF; the disease is skin basal cell carcinoma.